secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-221863
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics appoints trauma expert Col. (Ret.) John Holcomb to Board
--------------------------------------------------------------------------

- Dr. John Holcomb elected as Class II director; term expires at 2026 annual meeting.
- Option granted for 4,174 shares vesting over three years under 2021 Equity Plan.
- Holcomb served 23 years in U.S. Army, pioneered combat casualty care; 780+ publications.
- Appointment aims to advance iNKT therapies into immune-mediated disease and pulmonary disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312525221863/0001193125-25-221863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312525221863/inkt-20250923.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-221863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer